GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Flerie AB (OSTO:FLERIE) » Definitions » EV-to-Revenue

Flerie AB (OSTO:FLERIE) EV-to-Revenue : 224.64 (As of Sep. 21, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Flerie AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Flerie AB's enterprise value is kr2,456.24 Mil. Flerie AB's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was kr10.93 Mil. Therefore, Flerie AB's EV-to-Revenue for today is 224.64.

The historical rank and industry rank for Flerie AB's EV-to-Revenue or its related term are showing as below:

OSTO:FLERIE' s EV-to-Revenue Range Over the Past 10 Years
Min: -61990.5   Med: 3019.96   Max: 138867
Current: 224.65

During the past 10 years, the highest EV-to-Revenue of Flerie AB was 138867.00. The lowest was -61990.50. And the median was 3019.96.

OSTO:FLERIE's EV-to-Revenue is ranked worse than
88.41% of 1044 companies
in the Biotechnology industry
Industry Median: 7.765 vs OSTO:FLERIE: 224.65

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-09-21), Flerie AB's stock price is kr42.75. Flerie AB's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was kr2.04. Therefore, Flerie AB's PS Ratio for today is 21.00.


Flerie AB EV-to-Revenue Historical Data

The historical data trend for Flerie AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flerie AB EV-to-Revenue Chart

Flerie AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,436.37 10,247.90 - - -1.60

Flerie AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.31 0.67 -1.60 -1.04 256.41

Competitive Comparison of Flerie AB's EV-to-Revenue

For the Biotechnology subindustry, Flerie AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Flerie AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Flerie AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Flerie AB's EV-to-Revenue falls into.



Flerie AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Flerie AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=2456.239/10.934
=224.64

Flerie AB's current Enterprise Value is kr2,456.24 Mil.
Flerie AB's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr10.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Flerie AB  (OSTO:FLERIE) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Flerie AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=42.75/2.036
=21.00

Flerie AB's share price for today is kr42.75.
Flerie AB's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Flerie AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Flerie AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Flerie AB Business Description

Traded in Other Exchanges
Address
Berzelius vag 13, Solna, SWE, 171 65
InDex Pharmaceuticals Holding AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The company's main asset is the drug candidate cobitolimod, which is being evaluated in the phase III study as a treatment for moderate to severe ulcerative colitis - a disabling, chronic inflammation of the colon. It has also developed a platform of patent-protected substances, so-called DNA-based Immunomodulatory Sequences, with the potential to be used in the treatment of various immunological diseases.

Flerie AB Headlines

No Headlines